vs
富兰克林柯维（FC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
富兰克林柯维的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.8倍（$64.0M vs $35.5M），富兰克林柯维净利率更高（-5.1% vs -304.2%，领先299.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -7.3%），富兰克林柯维自由现金流更多（$-1.6M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 2.2%）
富兰克林柯维总部位于美国犹他州盐湖城，是一家专业培训指导企业，面向各类组织与个人提供领导力提升、个人效能成长与业务执行领域的培训及评估服务。公司由富兰克林奎斯特与柯维领导力中心于1997年合并成立，最为人熟知的产品包括富兰克林柯维规划系统等。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FC vs RXRX — 直观对比
营收规模更大
FC
是对方的1.8倍
$35.5M
营收增速更快
RXRX
高出689.0%
-7.3%
净利率更高
FC
高出299.1%
-304.2%
自由现金流更多
FC
多$45.7M
$-47.3M
两年增速更快
RXRX
近两年复合增速
2.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.0M | $35.5M |
| 净利润 | $-3.3M | $-108.1M |
| 毛利率 | 75.5% | 59.8% |
| 营业利润率 | -5.7% | -304.8% |
| 净利率 | -5.1% | -304.2% |
| 营收同比 | -7.3% | 681.7% |
| 净利润同比 | -378.5% | 39.6% |
| 每股收益（稀释后） | $-0.27 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCRXRX
| Q4 25 | $64.0M | $35.5M | ||
| Q3 25 | $71.2M | $5.2M | ||
| Q2 25 | $67.1M | $19.2M | ||
| Q1 25 | $59.6M | $14.7M | ||
| Q4 24 | $69.1M | $4.5M | ||
| Q3 24 | $84.1M | $26.1M | ||
| Q2 24 | $73.4M | $14.4M | ||
| Q1 24 | $61.3M | $13.8M |
净利润FCRXRX
| Q4 25 | $-3.3M | $-108.1M | ||
| Q3 25 | $4.4M | $-162.3M | ||
| Q2 25 | $-1.4M | $-171.9M | ||
| Q1 25 | $-1.1M | $-202.5M | ||
| Q4 24 | $1.2M | $-178.9M | ||
| Q3 24 | $12.0M | $-95.8M | ||
| Q2 24 | $5.7M | $-97.5M | ||
| Q1 24 | $874.0K | $-91.4M |
毛利率FCRXRX
| Q4 25 | 75.5% | 59.8% | ||
| Q3 25 | 75.5% | -183.8% | ||
| Q2 25 | 76.5% | -4.9% | ||
| Q1 25 | 76.7% | -48.0% | ||
| Q4 24 | 76.3% | -181.4% | ||
| Q3 24 | 78.1% | 53.7% | ||
| Q2 24 | 76.6% | 36.2% | ||
| Q1 24 | 76.4% | 19.1% |
营业利润率FCRXRX
| Q4 25 | -5.7% | -304.8% | ||
| Q3 25 | 11.1% | -3327.6% | ||
| Q2 25 | -3.3% | -916.8% | ||
| Q1 25 | -2.4% | -1297.9% | ||
| Q4 24 | 2.1% | -4042.4% | ||
| Q3 24 | 21.3% | -377.1% | ||
| Q2 24 | 11.4% | -697.4% | ||
| Q1 24 | 2.4% | -698.4% |
净利率FCRXRX
| Q4 25 | -5.1% | -304.2% | ||
| Q3 25 | 6.1% | -3135.3% | ||
| Q2 25 | -2.1% | -894.2% | ||
| Q1 25 | -1.8% | -1373.3% | ||
| Q4 24 | 1.7% | -3935.5% | ||
| Q3 24 | 14.2% | -367.5% | ||
| Q2 24 | 7.8% | -676.6% | ||
| Q1 24 | 1.4% | -662.4% |
每股收益（稀释后）FCRXRX
| Q4 25 | $-0.27 | $-0.17 | ||
| Q3 25 | $0.34 | $-0.36 | ||
| Q2 25 | $-0.11 | $-0.41 | ||
| Q1 25 | $-0.08 | $-0.50 | ||
| Q4 24 | $0.09 | $-0.56 | ||
| Q3 24 | $0.89 | $-0.34 | ||
| Q2 24 | $0.43 | $-0.40 | ||
| Q1 24 | $0.06 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.5M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $54.0M | $1.1B |
| 总资产 | $221.3M | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FCRXRX
| Q4 25 | $17.5M | $743.3M | ||
| Q3 25 | $31.7M | $659.8M | ||
| Q2 25 | $33.7M | $525.1M | ||
| Q1 25 | $40.4M | $500.5M | ||
| Q4 24 | $53.3M | $594.4M | ||
| Q3 24 | $48.7M | $427.6M | ||
| Q2 24 | $36.6M | $474.3M | ||
| Q1 24 | $40.9M | $296.3M |
总债务FCRXRX
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
股东权益FCRXRX
| Q4 25 | $54.0M | $1.1B | ||
| Q3 25 | $66.9M | $1.0B | ||
| Q2 25 | $65.6M | $919.1M | ||
| Q1 25 | $72.5M | $933.9M | ||
| Q4 24 | $80.6M | $1.0B | ||
| Q3 24 | $83.1M | $524.6M | ||
| Q2 24 | $72.2M | $584.4M | ||
| Q1 24 | $70.8M | $401.2M |
总资产FCRXRX
| Q4 25 | $221.3M | $1.5B | ||
| Q3 25 | $242.9M | $1.4B | ||
| Q2 25 | $218.3M | $1.3B | ||
| Q1 25 | $221.3M | $1.3B | ||
| Q4 24 | $239.9M | $1.4B | ||
| Q3 24 | $261.5M | $726.5M | ||
| Q2 24 | $221.0M | $775.9M | ||
| Q1 24 | $221.9M | $557.8M |
负债/权益比FCRXRX
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.0K | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | $-47.3M |
| 自由现金流率自由现金流/营收 | -2.5% | -133.1% |
| 资本支出强度资本支出/营收 | 2.7% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $5.9M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FCRXRX
| Q4 25 | $98.0K | $-46.1M | ||
| Q3 25 | $9.9M | $-117.4M | ||
| Q2 25 | $6.3M | $-76.4M | ||
| Q1 25 | $-1.4M | $-132.0M | ||
| Q4 24 | $14.1M | $-115.4M | ||
| Q3 24 | $21.9M | $-59.2M | ||
| Q2 24 | $8.2M | $-82.2M | ||
| Q1 24 | $12.8M | $-102.3M |
自由现金流FCRXRX
| Q4 25 | $-1.6M | $-47.3M | ||
| Q3 25 | $5.7M | $-117.6M | ||
| Q2 25 | $4.5M | $-79.6M | ||
| Q1 25 | $-2.6M | $-133.8M | ||
| Q4 24 | $13.1M | $-116.7M | ||
| Q3 24 | $20.8M | $-63.8M | ||
| Q2 24 | $7.3M | $-83.4M | ||
| Q1 24 | $12.1M | $-109.0M |
自由现金流率FCRXRX
| Q4 25 | -2.5% | -133.1% | ||
| Q3 25 | 8.0% | -2272.5% | ||
| Q2 25 | 6.7% | -413.9% | ||
| Q1 25 | -4.4% | -907.4% | ||
| Q4 24 | 19.0% | -2567.7% | ||
| Q3 24 | 24.7% | -244.6% | ||
| Q2 24 | 9.9% | -578.5% | ||
| Q1 24 | 19.8% | -789.9% |
资本支出强度FCRXRX
| Q4 25 | 2.7% | 3.5% | ||
| Q3 25 | 5.9% | 4.7% | ||
| Q2 25 | 2.7% | 16.4% | ||
| Q1 25 | 2.1% | 12.4% | ||
| Q4 24 | 1.4% | 28.6% | ||
| Q3 24 | 1.3% | 17.5% | ||
| Q2 24 | 1.2% | 8.2% | ||
| Q1 24 | 1.0% | 48.2% |
现金转化率FCRXRX
| Q4 25 | — | — | ||
| Q3 25 | 2.27× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 11.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 14.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
